Skip to main content

Table 1 Clinical information about patients with RA and controls

From: Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways

Group

RA

OA

HC

Sample size, n

83

67

88

Age, yr, mean ± standard deviation

58.30 ± 13.01

56.78 ± 13.98

55.73 ± 15.19

Sex, n

   

 Male

22

17

20

 Female

61

50

68

Mean duration of disease, mo (range)

53.27 (1–456)

46.31 (1–323)

Stages of disease, n

   

 Early RA (≤12 mo)

30

  

 Late RA (>12 mo)

53

  

Activity of disease, n

   

 Remission (DAS28 < 2.6)

10

 Low (2.6 ≤ DAS28 ≤ 3.2)

16

 Moderate (3.2 < DAS28 ≤ 5.1)

45

 High (DAS28 > 5.1)

12

Manifestations of disease, n

   

 Extraarticular

23

 Limited joint manifestations

60

Drug use before study

  1. RA rheumatoid arthritis, OA osteoarthritis, HC healthy controls, DAS28 28-joint Disease Activity Score